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Objective. Randomized controlled trials (RCTs) on di’ao xinxuekang capsule (XXK) in treating angina pectoris were published
only in Chinese and have not been systematically reviewed particularly for comparing XXK with isosorbide dinitrate (ISDN). This
study aims to provide a comprehensive PRISMA compliant and internationally accessible systematic review and meta-analysis to
evaluate the eﬃcacies of XXK and ISDN in treating angina pectoris. Methods. The RCTs published between 1989 and 2011 on
XXK and ISDN in treating angina pectoris were selected according to speciﬁc criteria. Meta-analysis was performed to evaluate
the symptomatic (SYMPTOMS) and electrocardiographic (ECG) improvements after treatment. Odds ratios (OR) were used to
measure eﬀect sizes. Subgroup analysis, sensitivity analysis, and metaregression were conducted to evaluate the robustness of the
results. Results. Seven RCTs with 550 participants were eligible. Overall ORs for comparing XXK with ISDN were 4.11 (95% CI:
2.57,6.55)inSYMPTOMSand2.37(95%CI:1.46,3.84)inECG.Subgroupanalysis,sensitivityanalysis,andmetaregressionfound
no signiﬁcant dependence of overall ORs upon speciﬁc study characteristics. Conclusion. The meta-analysis of eligible but limited
RCTs demonstrates that XXK seems to be more eﬀective than ISDN in treating angina pectoris. Further RCTs of high quality are
warranted to be conducted for update of the results of this meta-analysis.
1.Introduction
Ischemic heart disease, an imbalance coronary blood ﬂow
and myocardial requirement [1], usually has symptomatic
discomfort in the chest, that is, angina pectoris [2], due
to coronary insuﬃciency and myocardium ischemia and
hypoxia [3]. Nitrates, calcium channel blockers, beta-recep-
tor blockers are common drugs for treating angina pectoris
[4]. Isosorbide dinitrate (ISDN) is one of the most eﬀective
and frequently used nitrates for treating angina pectoris
[3, 5]. Di’ao xinxuekang (XXK) capsule is a second-class new
drug of China for treating angina pectoris [6]. The main
components of XXK are extracted from the rhizomes of Dio-
scorea panthaica Prain et Burkill and Dioscorea nipponica
Makino [7].
Randomized controlled trials (RCTs) on treatments of
angina pectoris found that XXK was more eﬀective than
aspirin [8]a n dm o r ee ﬀective than some Chinese medicinal
formulationsincludingcompounddanshen,guanxinsuquan
pills, and danshen dripping pills [9, 10]. A previous sys-
tematic review published in 2010 [11] suggested that XXK
were more eﬀective than danshen tablet but did not cite any
eligible RCT and did not report any subgroup or sensitivity
analysis. XXK and danshen dripping pills are two popular
Chinese medicinal products often compared with ISDN in
treating angina pectoris [12–15]. A recent systematic review
published in 2011 [16] indicated that danshen dripping
pills was more eﬀective than ISDN. Furthermore, there is
no systematic review or meta-analysis of RCTs comparing
XXK with conventional nitrates such as ISDN. As such,
it is not clear about whether XXK is more eﬀective than
ISDN in treating angina pectoris. This study aims to conduct
a comprehensive, PRISMA-compliant [17], internationally2 Evidence-Based Complementary and Alternative Medicine
accessible, and timely meta-analysis, with subgroup and
sensitivity analyses of RCTs to compare the eﬃcacies of XXK
and ISDN in treating angina pectoris.
2. Methods
2.1. Study Selection Criteria. RCTs published in Chinese or
Englishbetween1989(i.e.,theyearofXXKlaunch)and2011
on comparing XXK with ISDN in treating angina pectoris
were screened. Inclusion criteria were as follow: (a) partici-
pants were suﬀering from and being treated for angina pec-
toris; (b) the study was claimed to be an RCT; (c) the study
c o m p a r e dX X Kw i t hI S D Ni ne ﬃcacy; (d) duration of treat-
ment (follow-up period) was at least four weeks.
Exclusioncriteriawereasfollow:(a)duplicatedorredun-
dant study; (b) XXK was used in combination with other
drugs; (c) ISDN was used in combination with other drugs;
(d) the study did not include symptomatic (SYMPTOMS)
improvement as the major outcome.
2.2. Search Strategies. RCT reports published between the
1989and2011weresearchedfromdatabasesincludingChina
National Knowledge Infrastructure (CNKI), WanFang Data,
China Master Theses Full-text Database (CMTD), China
Doctor Dissertations Full-text Database (CDMD), Medline,
PubMed, Cochrane Library, ScienceDirect and EMbase. The
last search was performed on 22 August 2011.
The search strategy was formulated mainly for searching
xinxuekang because of few publications on the drug. For in-
stance,WanFangDatawassearchedwithsuchasimplequery
as: ((“guanxinbing (heart disease)” in title or “xinjiaotong
(angina pectoris)” in title) and “xinxuekang” in abstract).
The exact search strategies and query syntax were slightly ad-
justed according to the users’ instructions from diﬀerent
databases.
2.3. Study Selection. Two reviewers (Y. Jia and C. Chen)
independently screened all retrieved studies according to
the eligibility criteria. Disagreement between reviewers was
resolved by consensus. A ﬂow diagram of study selection was
generated according to the PRISMA requirements [17].
2.4. Data Extraction. Two reviewers (Y. Jia and C. Ng) inde-
pendently extracted data items comprised (a) publication
year;(b)numberofauthors;(c)trialdates;(d)baselinecom-
parizson of participants between groups; (e) sample size; (f)
outcome measures; (g) dosage and treatment duration; (h)
incidence of adverse events (AE).
2.5. Quality Assessment of Included Studies. Two reviewers
(Y. Jia and C. Chen) independently assessed the quality of
the included studies according to the Jadad scale [18], the M
scale [16] and the Cochrane risk of bias tool [19]. The Jadad
scale focused on three criteria including “randomization,”
“blinding,” and “dropouts” for assessing the quality of RCT.
The M scale was modiﬁed from the Jadad scale with two
additional criteria “baseline comparison of participants” and
“adverse event report.” The Cochrane risk of bias tool was
designed for more detailed assessment including criteria for
(a) allocation concealment, (b) blinding of participants, (c)
personnel and outcome assessment, (d) incomplete outcome
data, (e) selective reporting, and (f) other biases [19].
2.6. Criteria for Symptomatic and ECG Improvements. Eﬀec-
tive symptomatic improvements should achieve at least 50%
(basic) or 80% (signiﬁcant) reduction in frequency of feel-
ing angina chest pain. Eﬀective ECG improvements should
achieve at least 0.05mV lowering at ST segment in ECG
(basic)ornearlynormal(signiﬁcant)ECGduringanexercise
test as suggested in the ACC/AHA guideline [3].
2.7. Meta-Analysis. Eﬀect sizes were presented by odds ratios
(OR) [20] and 95% conﬁdence intervals (CI) [21]. Overall
meta-analysis and subgroup analysis employed the random-
eﬀects model because the homogeneity of the studies could
notbeguaranteed.Heterogeneityamongstudieswasassessed
by chi-squared (χ2)a n dI-squared (I2)[ 22].
2.8.SubgroupandSensitivityAnalysis. Subgroupanalysiswas
conducted to evaluate the overall eﬀects in possible sub-
groups which were grouped according to the characteristics
of the studies, including year of publication, number of
authors, follow-up period, sample sizes, study periods,
qualityofthestudies(Mscore),andimprovementsinSYMP-
TOMS and ECG. Mann-Whitney-Wilcoxon test was used to
analyze the diﬀerence between subgroups. Sensitivity analy-
ses were performed after excluding some studies to assess the
inﬂuence of such studies on the overall result of this meta-
analysis.
2.9. Metaregression and Risk of Bias across Studies. Funnel
plots[23],Begg’srankcorrelationtest[24],andEgger’slinear
regression test [25] were employed to assess the publication
bias. Metaregression [26] was conducted to ﬁnd the possible
relationshipbetweentheeﬃcacyandthefactorssuchassam-
ple sizes, M score, years of publication, and quality of RCTs.
2.10. Adverse Events. AEs of RCTs including nonreported
AEs, types and frequency of AEs reported were surveyed for
incidence of AEs during XXK and ISDN treatments.
2.11.StatisticalAnalysis. Meta-analysisandforestplotgener-
ation were performed with Review Manager 5 [27]. Metare-
gression and funnel plot generation was conducted with
Stata software version 11 (StataCorp LP, USA). Statistical
software R [28] was used to perform conventional statis-
tical analysis, including Spearman correlation and Mann-
Whitney-Wilcoxon unpaired two-sample test. P values lower
than 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Study Selection. The process of study selection was
depicted in Figure 1. The database search found 435 records,Evidence-Based Complementary and Alternative Medicine 3
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China National Knowledge Infrastructure
WanFang Data
China Master Theses Full-text Database
China Doctor Dissertations Full-text Database
PubMed
Medline                               
Cochrane Library 
Records after searching
database
Full-text records for screening
Records excluded:
Combined use of drugs   
Non SYMPTOMS data   
Records included 
(n = 209)
(n = 190)
(n = 24)
(n = 6)
(n = 2)
(n = 2)
(n = 2)
(n = 435)
(n = 40)
(n = 7)
(n = 31)
(n = 2)
Records excluded:
Redundant records
Review records
Non-IHD
Non-RCT
Non-ISDN in control group
(n = 15)
(n = 4)
(n = 5)
(n = 139)
(n = 232)
Figure 1: Process of searching and screening studies.
Table 1: Summary of the included studies evaluating the eﬃcacy of XXK in treating angina pectoris.
Study No. of
authors
Trail
date
Sample
size
Follow-up
period Comparable AEs Outcome
measures
XXK daily
dosage
ISDN daily
dosage
Jadad
score Ms c o r e
Zeng et al. [29] 6 0 34 28 days 1 1 SYM, ECG 6 pills 40mg 2 4
Dai [30] 1 1 120 28 days 0 0 SYM 6 pills 30mg 2 2
Hu [31] 1 0 8 4 2 8d a y s 1 1 S Y M ,E C G 6p i l l s 3 0m g 2 4
Li and Zhang [34] 2 1 6 0 2 8d a y s 0 1 S Y M 6p i l l s 6 0m g 2 3
Qu [32] 1 1 6 0 2 8d a y s 1 0 S Y M ,E C G 6p i l l s 3 0m g 2 3
Shen [33] 1 1 132 28 days 0 1 SYM, ECG 6 pills 30mg 2 3
Zhu et al. [35] 5 1 60 28 days 1 0 SYM, ECG 6 pills 30mg 2 3
XXK is di’ao xinxuekang capsule; ISDN is isosorbide dinitrate; SYM is SYMPTOMS; ECG is electrocardiogram; AEs is adverse events; Numbers 1 and 0 in
“Trial date” mean that study reported or did not report the trial date, respectively; Numbers 1 and 0 in “Comparable” mean that the study reported the
comparability between the experiment and control groups (1) or the study did not report that (0).
including 209 records from CNKI, 190 records from Wan-
FangData,24recordsfromCMTD,6recordsfromCDMD,2
recordsfromPubMed,2recordsfromMedline,and2records
from the Cochrane Library. According to the prespeciﬁed
selection criteria described in the section Methods, only
seven studies [29–35] were found eligible for further quality
assessment and meta-analysis.
3.2. Study Characteristics. Table 1 lists the main characteris-
tics of the included studies. All of the studies were published
in Chinese language between 1993 and 2007 with a total of
550 participants. The mean sample size was 78.6 (median =
60.0; 95% CI: 52.2, 105.0). The follow-up periods were all
28 days. The daily dosage of XXK was 6 pills in all studies.
The daily dosages of ISDN were 30mg in ﬁve studies, 40mg
and60mgintheothertwostudies.Allsevenincludedstudies
reported SYMPTOMS changes as outcome measures while
ﬁve studies [29, 31–33, 35] also reported ECG changes.
3.3. Quality Assessment of Included Studies. Table 1 lists the
results of quality assessment according to the Jadad and
M scale. All included studies were scored 2 according to4 Evidence-Based Complementary and Alternative Medicine
Study or subgroup
XXK
Events
ISDN
Events
Odds ratio
M-H, random, 95% CI
6.7% 2.15 [0.36, 12.76]
59 66 46 66 22.3%
12 16 14 18
Total events
Odds ratio
M-H, random, 95% CI
ISDN XXK
0.02 0.1 1 10 50
Total Total Weight
Dai, 2000 45 60 18 60 29.6% 7 [3.13, 15.64]
Hu, 2009 38 43 25 41 16.1% 4.86 [1.58, 14.97]
Li, 2000
Qu, 2006
Shen, 1993
Zeng, 1996
Zhu, 2007
Total (95% CI)
237
Heterogeneity:  = 0.02;  = 6.36, df = 6 (P = 0.38); I2 = 6%
Test for overall eﬀect: Z = 5.93 (P<0.00001)
29 30 24 30 4.5% 7.25 [0.82, 64.46]
28 30 26 30
3.66 [1.43, 9.41]
26 30 19 30 12.5% 3.76 [1.04, 13.65]
8.4% 0.86 [0.18, 4.19]
275 275 100% 4.11 [2.57, 6.55]
172
τ2 χ2
Figure 2: Forest plot of outcome measure SYMPTOMS.
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Hu, 2009 19.8%
8.2% Qu, 2006
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Figure 3: Forest plot of outcome measure ECG.
the Jadad scale (between 0 and 5 points), in consistency with
the average quality of Chinese RCTs [36].
According to M scale, four RCTs scored three, two RCTs
scored two, and one RCT scored one. Four included studies
[29, 31, 32, 35] reported baseline comparison of participants
inexperimentandcontrolgroup.Threeincludedstudies[30,
32, 35] did not report AEs. One included study [29]r e p o rt e d
types of AEs. Three included studies [31, 34, 35]r e p o r t e d
types and number of AEs.
Cochrane risk of bias tool also gave similar ratings, that
is, (a) unclear bias in random sequence generation; (b) high
bias in allocation concealment; (c) high bias in blinding of
participants; (d) personnel and outcome assessment; (e) low
bias in incomplete outcome data; (f) low bias in selective
reporting; (g) unclear bias in other bias.
3.4. Individual Studies and Their Synthesis. As shown in
Figure 2, the overall OR of SYMPTOMS was 4.11 (95% CI =
2.57–6.55, Z = 5.93, P<0.00001) with a heterogeneity
(τ = 0.02, I2 = 6%, P = 0.38) among the seven studies
with SYMPTOMS outcome. Figure 3 shows that the overall
OR of ECG was 2.37 (95% CI = 1.46–3.84, Z = 3.50,
P = 0.0005) with a heterogeneity (τ = 0, I2 = 0%, P =
0.57) among the ﬁve studies with ECG outcome. Both the
ORs of SYMPTOMS and ECG indicated that XXK is more
eﬀective than ISDN in treating angina pectoris. The overall
OR of SYMPTOMS was bigger than that of ECG although
the correlation in ORs between SYMPTOMS and ECG was
not statistically signiﬁcant (P = 0.6833).
3.5. Subgroup and Sensitivity Analysis. Based on study char-
acteristics including M score (≤3o r>3), years of publication
(before or after 1 January 2005), number of authors (1
or >1), dates of trial (reported or non-reported), baseline
comparison of participants (yes or no), sample sizes (<78
or ≥78), and reports of AEs (yes or no), subgroup analysis
or sensitivity analysis were performed and their results are
shown in Tables 2 and 3. Wilcoxon test for comparing the
ORs between subgroups in terms of SYMPTOMS and ECG
found no statistically signiﬁcant diﬀerences.
When the improvements in SYMPTOMS were raised to
a signiﬁcant level from the basic level, the results remain
eﬀective and statistically signiﬁcant (OR = 1.83, 95% CI =
1.20–2.82, Z = 2.77, P = 0.006).The overall ECG OR
decreased from 2.37 to 1.60 (95% CI = 0.98–2.60, Z = 1.88,
P = 0.06)withaheterogeneity(τ = 2.38,I2 =0%,P = 0.67).
The results indicated there was not heterogeneity. Likewise,
results of Spearman correlation analysis indicated there was
not statistical signiﬁcance (P = 0.95) between them.
3.6. Metaregression. Table 4 shows the results of meta-
regression between logOR and study characteristics. AsEvidence-Based Complementary and Alternative Medicine 5
Table 2: Subgroups and sensitivity analysis based on ORs of SYMPTOMS outcomes.
Group No. of
studies
No. of
participants OR Wilcoxon test 95% CI ZP (eﬀect) I2 χ2 P (het)
Ms c o r e ≤3 5 432 4.76 W = 7 2.85, 7.95 5.96 <0.00001 0% 2.21 0.70
>3 2 118 2.24 P = 0.4386 0.41, 12.17 0.94 0.35 67% 3.06 0.08
Sample size <78 4 214 2.49 W = 4 1.09, 5.68 2.17 0.03 3% 3.09 0.38
≥78 3 336 5.22 P = 0.4795 3.05, 8.93 6.03 <0.00001 0% 1.07 0.59
No. of authors 1 4 396 4.85 W = 6 2.90, 8.11 6.01 <0.00001 0% 1.94 0.58
>1 3 154 2.61 P = 1 0.82, 8.36 1.62 0.11 35% 3.06 0.22
Publication year <2005 4 346 3.84 W = 7 1.65, 8.93 3.12 0.002 47% 5.71 0.13
≥2005 3 204 3.82 P = 0.7237 1.78, 8.21 3.44 0.0006 0% 0.58 0.75
Trial date Reported 5 432 4.76 W = 7 2.85, 7.95 5.96 <0.000
01 0% 2.21 0.70
Not
reported 2 118 2.24 P = 0.4386 0.41, 12.17 0.94 0.35 67% 3.06 0.08
Comparable Reported 4 238 2.83 W = 2 1.36, 5.89 2.78 0.005 10% 3.35 0.34
Not
reported 3 312 5.45 P = 0.1573 3.02, 9.83 5.64 <0.00001 0% 1.12 0.57
AEs Reported 4 310 3.30 W = 6 1.58, 6.88 3.18 0.0001 21% 3.78 0.29
Not
reported 3 240 5.17 P = 1 2.74, 9.78 5.06 <0.00001 0% 1.71 0.43
Improvement >50% 7 550 4.11 W = 7 2.57, 6.55 5.93 <0.00001 6% 6.36 0.38
>80% 5 370 1.83 P = 0.2506 1.20, 2.82 2.77 0.006 0% 1.10 0.89
CI is conﬁdence interval. Mann-Whitney-Wilcoxon test was performed on ORs of SYMPTOMS. Z and P (eﬀect) evaluated the statistics of overall eﬀect; I2,
χ2,a n dP (het) were computed to assess heterogeneity.
Table 3: Subgroups and sensitivity analysis based on ORs of ECG outcomes.
Group No. of
studies
No. of
participants OR Wilcoxon
test 95% CI ZP (eﬀect) I2 χ2 P (het)
Ms c o r e ≤3 3 252 2.73 W = 4 1.52, 4.91 3.35 0.0008 0% 0.24 0.89
>3 2 118 1.65 P = 0.5637 0.49, 5.57 0.8 0.42 49% 1.98 0.16
Sample size <78 3 154 1.71 W = 2 0.77, 3.84 1.31 0.19 0% 1.93 0.38
≥78 2 216 2.84 P = 0.5637 1.56, 5.20 3.39 0.0007 0% 0 0.99
No. of authors 1 3 276 2.91 W = 6 1.65, 5.14 3.69 0.000 2 0% 0.05 0.97
>1 2 94 1.39 P = 0.0833 0.54, 3.55 0.68 0.5 4% 1.05 0.31
Publication year <2005 2 166 1.75 W = 1 0.54, 5.74 0.93 0.35 60% 2.47 0.12
≥2005 3 204 2.69 P = 0.2482 1.29, 5.60 2.63 0.008 0% 0.24 0.89
Trial date Reported 2 118 1.65 W = 2 0.49, 5.57 0.8 0.42 49% 1.98 0.16
Not reported 3 252 2.73 P = 0.5637 1.52, 4.91 3.35 0.0008 0% 0.24 0.89
Comparable Reported 4 238 2.06 W = 2 1.08, 3.93 2.19 0.03 0% 2.48 0.48
Not reported 1 132 2.83 P = 1 1.37, 5.85 2.81 0.005 NA NA NA
AEs Reported 3 250 2.22 W = 2 1.14, 4.32 2.33 0.02 25% 2.66 0.26
Not reported 2 120 2.54 P = 0.5637 0.94, 6.90 1.83 0.07 0% 0.21 0.65
Improvement >50% 5 370 2.37 W = 14 1.46, 3.84 3.5 0.0005 0% 2.90 0.57
>80% 5 370 1.60 P = 0.7540 0.98, 2.60 1.88 0.06 0% 2.38 0.67
CI is conﬁdence interval. NA is not available; Mann-Whitney-Wilcoxon test was performed on ORs of ECG. Z and P (eﬀect) evaluated the statistics of overall
eﬀect; I2, χ2,a n dP (het) were computed to assess heterogeneity.
theresultsofmetaregressionwerenotstatisticallysigniﬁcant,
there seems to be no obvious correspondence of the ef-
ﬁcacy to any study characteristic.
3.7. Risk of Bias across Studies. Publication biases were
assessed by funnel plots (Figure 4), which found no obvious
asymmetry for SYMPTOMS and ECG. The Begg’s test
(SYMPTOMS: Z = −0.75, P = 0.453; ECG: Z = −0.98,
P = 0.327) and the Egger’s test (SYMPTOMS: t = −1.15,
P = 0.301; ECG: t = −0.70, P = 0.536) also found no stati-
stically signiﬁcant publication bias.
3.8. Adverse Events. Three studies [30, 32, 35]o fs e v e ni n -
cluded studies did not report AEs. The AEs among 155 parti-
cipants in the studies with AE reports were mainly headache
and dizziness. A study [29] reported that the AE incidence of6 Evidence-Based Complementary and Alternative Medicine
Table 4: Metaregression of basic characteristics of RCTs and ORs of SYMPTOMS and ECG outcomes.
LogOR No. of RCTs No. of participants Factor tested Coeﬃcient tP
Publication year 0.0200 0.43 0.685
No. of authors −0.2106 −1.63 0.165
Trail date 0.5646 1.00 0.365
SYMPTOMS 7 550 Sample size 0.0069 1.52 0.190
Comparable −0.6369 −1.38 0.227
AEs −0.4280 −0.89 0.412
Ms c o r e −0.4829 −1.56 0.180
Publication year 0.0097 0.26 0.809
No. of authors −0.1796 −1.46 0.239
Trail date 0.4354 0.83 0.469
ECG 5 370 Sample size 0.0073 1.10 0.354
Comparable −0.3195 −0.64 0.565
AEs −0.0911 −0.16 0.886
Ms c o r e −0.4354 −0.83 0.469
Metaregression was conducted by residual (restricted) maximum likelihood (REML) with Knapp-Hartung modiﬁcation.
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Figure 4: Funnel plots of (a) the included studies with SYMPTOMS data and (b) the included studies with ECG data.
ISDN was 22.22% (4/18) and the AE incidence of XXK was
12.50% (2/16). Another study [34] reported that of the AE
incidence of ISDN was 13.33% (4/30) and the AE incidence
of XXK was 0% (0/30). The third study [33] reported that
the AE incidence of ISDN was 28.79% (19/66) and the AE
incidenceofXXKwas0%(0/66).Thelaststudy[31]reported
no AE for all participants. The overall AE incidence of XXK
at 1.30% (2/155) was lower than that of ISDN at 17.42%
(27/155).
4. Discussion
This study provides a PRISMA-compliant systematic review
and meta-analysis based on the RCTs of XXK and ISDN to
evaluate the eﬃcacy in treating angina pectoris. Seven RCTs
with 550 participants were found eligible and thus included.
Overall ORs of SYMPTOMS and ECG were 4.11 and 2.37,
respectively and were statistically signiﬁcant (P<0.05). Sub-
group analysis, sensitivity analysis, and metaregression on
various parameters showed this positive evidence to be roz-
bust. This meta-analysis found that XXK seems to be more
eﬀective than ISDN in treating angina pectoris.
This systematic review is comprehensive, reliable, and
PRISMA-compliant. In this meta-analysis, (a) a comprehen-
sive search for RCTs published between 1989 and 2011 were
performed; (b) only the studies with XXK and ISDN as
single-drug interventions were included; (c) subgroup anal-
ysis, sensitivity analysis, and metaregression were performed
according to the basic characteristics of included studies; (d)
publication bias was assessed not only by funnel plots but
also by the Begg’s test and Egger’s test.
ThisstudyindicatedXXKseemstobemoreeﬀectivethan
ISDN in treating angina pectoris. The active components of
XXK are steroidal saponin glycosides, among which Saponin
DP 1–8 is a major component [37]. XXK were able toEvidence-Based Complementary and Alternative Medicine 7
(a) maintain the activity of Ca2+-ATP enzyme and Na+-
K+-ATP enzyme through free radicals removal; (b) protect
myocardial cells from ischemia and maintain the integrity
of myocardial cell membrane; (c) protect myocardial cells
through dilated coronary arteries, reduced coronary resis-
tance, increased coronary blood ﬂow, improved blood and
oxygen supply to myocardium; (d) improve myocardial
ischemia symptoms through reducing myocardial oxygen
consumption and enhancing tolerance of myocardium to
hypoxia [38, 39].
A major limitation of this systematic review, like other
systematic reviews on Chinese RCTs [16], is the quality
of included studies. Only 6.8% RCTs on 20 common dis-
easespublishedfromJanuary1994toJune2005areauthentic
RCTs conducted in China National Knowledge Infrastruc-
ture electronic database [40]. Most of the included studies
scored only 2 at the Jadad scale, which is a scale ranged
between 0 and 5. Neither allocation concealment nor blind-
ing was mentioned in the included studies. Four out of seven
includedstudiesscoredonly3attheMscale(rangedbetween
1and7).Althoughwefoundnostatisticallysigniﬁcantdiﬀer-
ence in the eﬀect sizes between diﬀerent grades of study
quality, further updates of this systematic review should be
required to conﬁrm the eﬃcacy of XXK over ISDN.
All studies included in this meta-analysis did not report
full outcome measure data. They only reported the results
based on the number of participants with diﬀerent responses
tothetreatments.Moreover,thefollow-upperiodofallstud-
ieswasonly28days;thus,toleranceofISDNovertimewould
not be estimated. Tolerance of ISDN was not adequately
considered in past meta-analyses of (even) western medi-
cine RCTs.
This systematic review included the studies comparing
XXK and ISDN and excluded the studies with combined
drugs. The dosages of XXK were in accordance with recom-
mended dosages (two pills each time, three times a day) of
the manufacturer. Daily dosages of ISDN ranged from 30mg
to60mg.TheguidelineofACC/AHA2002suggestedtheoral
dosage range of ISDN to be 5–80mg each time twice or three
t i m e sad a y .Ap r evi o u ss t u d y[ 41] found that high dosages of
ISDN were not better than low dosages of ISDN in treating
angina pectoris. The interpretation of the trial results in this
systematicreviewwouldnotbecomplicatedbythecombined
use of DSP or ISDN with other drugs.
Incidence of AEs due to XXK (1.30%) was lower than
those due to ISDN (17.42%). All seven included studies did
not report AEs in a standard format. Three studies did not
report AEs at all. Thus, the safety of XXK could not be thoro-
ughlyevaluatedalthoughitiswellappreciatedintheresearch
community that RCTs should report AEs properly [42].
5. Conclusion
The meta-analysis of eligible but limited RCTs demonstrates
that XXK seems to be more eﬀective than ISDN in treating
angina pectoris. Further RCTs of high quality are warranted
to be conducted for update of the results of this meta-
analysis.
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